Thank you for your message about A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors. You must verify your email address to receive further communication about this trial. Please check your email for a verification message.
We're sorry, your verification code has expired. Please submit another form using the button below to receive communications about your preferred clinical trial study.
Clinical Trial Study Email Verified A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors